[PDF] Top 20 Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
Has 10000 "Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia" found on our website. Below are the top 20 most common "Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia".
Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
... involved in other crucial metabolic pathways such as the pentose phosphate path- way (PPP) coupled to NADPH production, glutathione/ redox recycling, and nucleotide biosynthesis ...prognosis in an ... Voir le document complet
18
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
... activity in a small number of ...obtained for the same drug in PBMC (from eight healthy donors) to define which drugs were most specific towards leukemic ...more leukemia specific (JQ1, 17AAG and ... Voir le document complet
12
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
... challenge in cancer ...present in these transcription-factor driven ...liability in EVI-positive AML. In considering the clinical translation of this finding, it is notable that cyclocreatine ... Voir le document complet
34
Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy
... USP7, for instance in T-cell acute lymphoblastic leukemia (T-ALL) in which the transcription factor NOTCH1 induces USP7 gene expression, and where USP7 controls the stability of NOTCH1 ... Voir le document complet
17
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
... inherent in retrospective registry-based studies by studying a large patient cohort, by double-checking the RIC/ MAC information and by using early NRM as primary endpoint for estimating the impact of TCI, ... Voir le document complet
12
Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the LEA program
... congestive therapy. Fifteen among these 23 (including 4 of 6 who received therapy) had improvement and, at last ...reported in the German as well as in the UK experience of childhood AML ... Voir le document complet
5
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
... inhibition in FLT3-ITD mutant driven MOLM-14 leukemic cells To mechanistically understand the regulation of the crosstalk between UPS and ALS in leukaemia, we investigated the role of proteaphagy which is ... Voir le document complet
24
Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia
... x FOR PEER REVIEW 3 of 17 ...Dysregulated in IDH1 Mutant Cells We first compared the proteome of IDH1 mutant HL60 cells to the one of IDH1 WT ...changes in proteins that are associated to pathways of ... Voir le document complet
19
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
... role in hematopoietic stem cells (HSC) proliferation and differentiation ...MSI2 in mice created a pre-leukemic phase [21] and its overexpression was found during transition from chronic to acute ... Voir le document complet
10
Analysis of the proteasome-autophagy crosstalk under proteotoxic stress conditions in acute myeloid leukemia
... Autophagy in cancer Loss of a survival pathway, such as autophagy, undermines ...interpreted in the context of cancer, the autophagy role in cancer, in effect, is ...explained in part ... Voir le document complet
222
Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?
... 18,19 In this issue of Bone Marrow Transplantation, Jedlickova et ...DLI in a cohort of 46 high-risk AML patients given grafts following a sequential treatment consisting of chemotherapy (FLAMSA) followed ... Voir le document complet
3
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations
... GSK-J4 in RUNX1 mut AML cells observed in vitro was most likely due to an off- target effect of ...GSK-J4. In response to the publication of GSK-J1/J4 as a specific inhibitor of KDM6A/B, Heinemann et ... Voir le document complet
89
Acute lymphoblastic leukemia in children
... Le nombre (n = 13 soit 16,5 %) d’échecs thé- rapeutiques (rechutes et patients réfractaires : plus de 25 % de blastes après l’induction) que nous avons observé est bas mais le taux de “r[r] ... Voir le document complet
7
Isolated granulocytic sarcoma of the pancreas: A tricky diagnostic for primary pancreatic extramedullary acute myeloid leukemia
... Cases presentation The first patient was a 45-year-old woman, without signifi- cant comorbidity, who was referred to our institution for surgery. Epigastric pain with jaundice began one month previously without ... Voir le document complet
6
Understanding the transcriptional control of EIF4E and its dysregulation in acute myeloid leukemia: role of NF-κB
... Mechanisms for Translation Initiation Alternative mechanisms for translation initiation have been previously described and involve cap-independent strategies 7 ...element in the ...programming ... Voir le document complet
154
Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials
... " # $ % No markup for post-processing Safaa M. Ramadan, MD, PhD * , , Stefan Suciu, PhD , Marian J.P.L. Stevens-Kroef, PhD * , , Roelof Willemze, MD, PhD , Sergio Amadori , Theo de Witte, MD * , , Bob ... Voir le document complet
3
Practical management of Chronic Myeloid Leukemia in Belgium
... TKI for the right patient, minimising their side effects, and enhancing patient compliance in order to achieve the best molecular response with the best quality of ...feasible for a limited number of ... Voir le document complet
17
Aberrant Chloride Intracellular Channel 4 Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia
... INTRODUCTION Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous hematopoietic ...decisions in AML patients with chromosomal abnormalities, which comprises 55–60% of all ... Voir le document complet
14
Considering personalized Interferon-β therapy for COVID-19
... 3. Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, ... Voir le document complet
8
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
... cells, in presence of an NK effector cell line, NK92 158 ...). In a clini- cal setting, ADCC or ADCP can be driven by effector cells such as NK cells or monocytes present in the ...cytotoxicity ... Voir le document complet
14
Sujets connexes